EUCTR2008-001696-30-ES进行中（未招募）不适用
Ensayo fase II, abierto, de un solo brazo de tratamiento para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de TMC278 en pacientes adolescentes de entre 12 y 18 años de edad infectados por el VIH-1, sin tratamiento antirretroviral previo.A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of TMC278 in antiretroviralnaïve HIV-1 infected adolescents aged 12 to < 18 years
Tibotec Pharmaceuticals Ltd.0 个研究点目标入组 35 人开始时间: 2008年10月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria are eligible for this trial:
- •1. Boys or girls, aged = 12 to <18 years.
- •2. Subject’s weight is = 40 kg.
- •3. Subject with documented chronic HIV-1 infection who is aware of his/her HIV-1
- •4. Subject willing and able to give consent. In case the subject’s age is below the cut-off age for consent (according to local regulations), their parent/caregiver should be able and willing to give consent, and the subject will be informed about the trial and asked to give positive assent.
- •5. Subject can comply with the protocol requirements.
- •6. Subject has, prior to screening, never been treated with a therapeutic HIV vaccine or an HIV drug with the exception of a single dose of NVP to prevent MTCT.
- •7. HIV-1 plasma viral load at screening = 5,000 HIV-1 RNA copies/mL (assayed by RNA
- •polymerase chain reaction [PCR] standard specimen procedure).
- •Note: To reassess eligibility, retesting of a screening value that leads to exclusion will be allowed only once during the screening period using an unscheduled visit.
- •8. In the judgment of the investigator, it is appropriate to initiate ARV therapy based on the subject’s medical condition and taking into account guidelines for the treatment of HIV-1 infection in children of this age group.
- •Note: Most current treatment guidelines recommend considering initiation of ART when CD4+ cell counts are < 350 cells/mm³. However, clinical situations may warrant
- •initiating ART with CD4+ cell counts > 350 cells/mm³. An example of such
- •situations would include rapidly declining CD4+ cell counts over time.
- •9. Results from the screening virco® TYPE HIV-1 demonstrate sensitivity to the selected N(t)RTIs using the lower CCO (indicated as maximal response” on the screening virco®TYPE HIV-1 result) or the BCO (indicated as susceptible”), whichever is applicable for the chosen background regimen.
- •10. Subject is able to swallow the TMC278 tablet as a whole (since the tablet cannot be chewed, broken, or crushed).
- •11. The subject agrees (or their parents/caregivers agree, in case the subject's age is below the cut-off age for consent according to local regulations, in which case the subject is informed and asked to give positive assent) not to start ART before the baseline visit.
- •12. General medical condition, in the investigator’s opinion, does not interfere with the assessments and the completion of the trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting one or more of the following criteria cannot be selected:
- •1. Any previous use of ARVs, with the exception of a single dose of NVP to prevent MTCT.
- •2. Having documented genotypic evidence of NNRTI resistance at screening or from
- •historical data available in the source documents, i.e., = 1 NNRTI RAM from the
- •following list (the list was compiled on the basis of the list of IAS-USA NNRTI RAMs23
- •and other relevant publications).
- •A098G V106M Y181C G190S
- •L100I V108I Y181I G190T
- •K101E E138A Y181V P225H
- •K101P E138G Y188C F227C
- •K101Q E138K Y188H M230I
- •K103H E138Q Y188L M230L
- •K103N E138R G190A P236L
- •K103S V179E G190C K238N
- •K103T V179D G190E K238T
- •V106A V179T G190Q Y318K
- •3. Previously documented HIV-2 infection.
- •4. Subject has a positive HLA-B*5701 test at screening (when the invesigator considers ABC/3TC as a background regimen). In case of a positive test, ABC/3TC cannot be administered, but instead, the investigator can select AZT/3TC as the background regimen. HLA-B*5701 testing is not required for subjects with prior documented negative results.
- •5. Use of disallowed concomitant therapy from 4 weeks prior to the baseline visit.
- •6. Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subject’s safety or adherence to the protocol.
- •7. Life expectancy less than 6 months.8. Subject has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness (Category C conditions according to the Centers for Disease Control and Prevention [CDC] Classification System for HIV-Infection 1993).
- •9. Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction, active and significant psychiatric disorders, clinical suspicion of adrenal insufficiency, hepatic impairment), or findings during screening or medical history that in the investigator’s opinion, would compromise the outcome of the trial.
- •10. Subject has a known or suspected acute (primary) HIV-1 infection.
- •11. Any current or history of adrenal disorder.
- •12. Previously demonstrated clinically significant allergy or hypersensitivity to any of the components of the investigational medication (TMC278) or the selected NRTIs. In this last case, the other N(t)RTI may be selected.
- •13. Receipt of any investigational drug or investigational vaccine within 90 days prior to the first administration of TMC278.
- •14. Pregnant or breastfeeding girl.
- •15. Heterosexually active girls of childbearing potential without the use of effective birth control methods or not willing to continue practicing these birth control methods from screening onwards until at least 30 days after last intake of TMC278.
- •16. Heterosexually active boys without the use of effective birth control methods or not willing to continue practicing these birth control methods from screening onwards until 30 days after last intake of TMC278.
- •17. Any grade 3 or 4 laboratory toxicity according to the Division of AIDS (DAIDS) grading table (see Section 8.2, Addendum 2), except for:
- •- grade 3 absolute neutrophil count;
- •- grade 3 platelets;
- •- grade 3 glucose elevation in diabetics;
- •- asymptomatic grade 3 pancreatic amylase elevation;
- •- asymptomatic grade 3 triglyceride / cholesterol / glucose elevation;
- •- asymptomatic grade 4 triglyceride elevation.
- •18. Subject has active tuberculosis and/or is being treated for tuberculosis at screening.
- •19. Subject has one or more of the following risk factors for QTc prolongation:
- •- a confirmed pr
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico de Fase II, de un solo brazo de tratamiento, con BIBW 2992 (Tovok?) en pacientes con cáncer de pulmón no microcítico seleccionados demográficamente y genotípicamente.A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patientsPacientes con cancer de pulmón no microcítico en estadío IIIB / IVMedDRA version: 9Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-001546-67-ESBoehringer Ingelheim España S.A.40
进行中（未招募）
不适用
Midostaurin in Indolent Systemic MastocytosisEUCTR2012-004868-22-NLniversity Medical Center Groningen
已完成
2 期
Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosismast cell disease10018865mastocytosisNL-OMON39686niversitair Medisch Centrum Groningen20
进行中（未招募）
1 期
Ensayo clínico fase II de un solo brazo, multicéntrico y prospectivo para la validación de biomarcadores en pacientes con cáncer colorrectal avanzado y/o metastásico con gen KRAS no mutado tratados con quimioterapia más cetuximab bisemanal como terapia de primera línea. - POSIBACancer colorrectal avanzado y/o metastásicoMedDRA version: 11Level: PTClassification code 10061451Term: Cáncer colorrectalMedDRA version: 11Level: PTClassification code 10052358Term: Cáncer metastásico colorrectalEUCTR2010-019236-12-ESGrupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)170
尚未招募
不适用
eoadjuvant Lazertinib Therapy in Resectable EGFR-Mutation Positive Lung Adenocarcinoma Patients Detected by Bronchoalveolar lavage fluid Liquid BiopsyNeoplasmsKCT0007214Konkuk University Medical Center40